The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-β receptor on dendritic cells potentiates tumour antigen-specific CD8(+) T cell immunity

Clinical and Experimental Immunology
Y-H AhnTae Woo Kim

Abstract

Dendritic cells (DCs) are promising therapeutic agents in the field of cancer immunotherapy due to their intrinsic immune-priming capacity. The potency of DCs, however, is readily attenuated immediately after their administration in patients as tumours and various immune cells, including DCs, produce various immunosuppressive factors such as interleukin (IL)-10 and transforming growth factor (TGF)-β that hamper the function of DCs. In this study, we used small interfering RNA (siRNA) to silence the expression of endogenous molecules in DCs, which can sense immunosuppressive factors. Among the siRNAs targeting various immunosuppressive molecules, we observed that DCs transfected with siRNA targeting IL-10 receptor alpha (siIL-10RA) initiated the strongest antigen-specific CD8(+) T cell immune responses. The potency of siIL-10RA was enhanced further by combining it with siRNA targeting TGF-β receptor (siTGF-βR), which was the next best option during the screening of this study, or the previously selected immunoadjuvant siRNA targeting phosphatase and tensin homologue deleted on chromosome 10 (PTEN) or Bcl-2-like protein 11 (BIM). In the midst of sorting out the siRNA cocktails, the cocktail of siIL-10RA and siTGF-βR generated the...Continue Reading

References

Dec 5, 1995·Proceedings of the National Academy of Sciences of the United States of America·T C WuD M Pardoll
Feb 29, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·K SatoT A Takahashi
Dec 20, 2000·The Journal of Experimental Medicine·J BanchereauK Palucka
Jun 11, 2003·Investigational New Drugs·Slawomir Wojtowicz-Praga
Jul 4, 2003·The Journal of Clinical Investigation·Tae Woo KimT-C Wu
Nov 26, 2003·Nature Immunology·Masato KuboAkihiko Yoshimura
May 4, 2004·Nature Medicine·Carl G FigdorCornelis J M Melief
Oct 21, 2004·Biochemical Society Transactions·M J RauhG Krystal
Dec 2, 2004·Nature Reviews. Immunology·Dmitry Gabrilovich
Apr 2, 2005·Nature Reviews. Immunology·Jacques Banchereau, A Karolina Palucka
Nov 12, 2005·The Journal of Biological Chemistry·Xiao-Jun QiPhilip H Howe
Jul 25, 2006·Nature Reviews. Cancer·Alexander J Muller, Peggy A Scherle
Feb 22, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ivan PerrotSerge Lebecque
May 4, 2007·The Journal of Clinical Investigation·Eli Gilboa
Mar 4, 2008·Cancer Immunology, Immunotherapy : CII·Patrizia StoitznerFranca Ronchese
Aug 30, 2008·Blood·Jinfang Zhu, William E Paul
Sep 8, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Meghan E TurnisCliona M Rooney
Dec 1, 2009·Future Medicinal Chemistry·Qing GePatrick Y Lu
Mar 1, 2012·Cancer Immunology, Immunotherapy : CII·Jing ZhangXiubao Ren
Aug 21, 2013·Immunological Reviews·Celeste GohYoung S Hahn

❮ Previous
Next ❯

Citations

Apr 6, 2016·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Karen FoguerMaria Helena Bellini
Feb 24, 2016·Expert Review of Vaccines·Andrew YangChien-Fu Hung
Nov 28, 2015·Seminars in Immunology·Paul A BeavisPhillip K Darcy
Oct 18, 2016·Cytotherapy·Rebecca S Abraham, Duane A Mitchell
Nov 5, 2016·Journal of Biomedical Science·Andrew YangChien-Fu Hung
Jun 23, 2015·Immunology Letters·Maria Teresa P de AquinoAnil Shanker
Jan 9, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Kevin Ita
Mar 5, 2017·Seminars in Cancer Biology·Mohanraj RamachandranMagnus Essand
Jun 13, 2018·Nucleic Acid Therapeutics·Francesco MaininiMichael R Eccles
Feb 9, 2018·Human Vaccines & Immunotherapeutics·Chutamas ThepmaleePa-Thai Yenchitsomanus
Feb 13, 2018·Experimental and Therapeutic Medicine·Qinglong MengYueying Ren
Oct 19, 2017·Experimental and Therapeutic Medicine·Jun WangLi Li Zou
Aug 1, 2019·International Journal of Oncology·Yu LiuXiaorong Qi
Sep 12, 2019·Biochemistry. Biokhimii︠a︡·M S VonskyM G Isaguliants
Sep 21, 2018·Frontiers in Immunology·Diana LlopizPablo Sarobe
Dec 9, 2020·Cancers·Amirhossein Bahreyni, Honglin Luo
Apr 3, 2020·Current Opinion in Biotechnology·Rita AhmedLana E Kandalaft
Mar 3, 2021·JCI Insight·Samuel T PellomCaroline Jochems
Aug 23, 2021·Journal of Controlled Release : Official Journal of the Controlled Release Society·Cao Dai PhungJong Oh Kim

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.